Technical Analysis for MRKR - Marker Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Bullish Engulfing | Bullish | -0.31% | |
| Lower Bollinger Band Walk | Weakness | -0.31% | |
| Inside Day | Range Contraction | -0.31% | |
| Wide Bands | Range Expansion | -0.31% | |
| Lower Bollinger Band Touch | Weakness | -0.31% | |
| Oversold Stochastic | Weakness | -0.31% | |
| MACD Bearish Centerline Cross | Bearish | 8.53% |
| Alert | Time |
|---|---|
| Lower Bollinger Band Support | about 16 hours ago |
| Down 5% | about 16 hours ago |
| Down 3% | about 16 hours ago |
| Down 2 % | about 16 hours ago |
| 60 Minute Opening Range Breakdown | about 17 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/07/2024
Marker Therapeutics, Inc. Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is also advancing various peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including its Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In addition, it develops a proprietary DNA expression technology, known as PolyStart, to improve the ability of the cellular immune system to recognize and destroy diseased cells. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Immunology Solid Tumors Immune System Immunotherapy Cancer Treatment Oncology Treatment Of Cancer Tumor Cancer Immunotherapy Cell Therapy Virotherapy Immunotherapies Ovarian Cancer Hematological Malignancies T Cell Her2 Her2/Neu Breast And Ovarian Cancer Tumor Cell Metastatic Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.1568 |
| 52 Week Low | 2.4377 |
| Average Volume | 35,565 |
| 200-Day Moving Average | 4.00 |
| 50-Day Moving Average | 3.29 |
| 20-Day Moving Average | 3.75 |
| 10-Day Moving Average | 3.55 |
| Average True Range | 0.41 |
| RSI (14) | 43.18 |
| ADX | 25.17 |
| +DI | 17.58 |
| -DI | 23.63 |
| Chandelier Exit (Long, 3 ATRs) | 3.80 |
| Chandelier Exit (Short, 3 ATRs) | 4.04 |
| Upper Bollinger Bands | 4.57 |
| Lower Bollinger Band | 2.92 |
| Percent B (%b) | 0.16 |
| BandWidth | 43.94 |
| MACD Line | -0.08 |
| MACD Signal Line | 0.04 |
| MACD Histogram | -0.1245 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.60 | ||||
| Resistance 3 (R3) | 3.58 | 3.41 | 3.53 | ||
| Resistance 2 (R2) | 3.41 | 3.31 | 3.43 | 3.51 | |
| Resistance 1 (R1) | 3.30 | 3.24 | 3.22 | 3.32 | 3.48 |
| Pivot Point | 3.13 | 3.13 | 3.09 | 3.15 | 3.13 |
| Support 1 (S1) | 3.02 | 3.03 | 2.94 | 3.04 | 2.88 |
| Support 2 (S2) | 2.85 | 2.96 | 2.87 | 2.85 | |
| Support 3 (S3) | 2.74 | 2.85 | 2.83 | ||
| Support 4 (S4) | 2.76 |
